Cosychem Technology(Tianjin) Co., Ltd. was established in 2010, focusing on building a key technology platform for nucleic acid drugs, achieving high-quality and low-cost raw materials, overcoming the challenges of organ targeted delivery,promoting the development of innovative pipelines, and driving the pipeline of indication expansion and cutting-edge therapeutic exploration.The company has secured a position in the core supply chain of leading domestic pharmaceutical firms, with multiple proprietary pipelines advancing to the preclinical stage and achieving commercialization. It boasts a diverse, interdisciplinary team of scientists with international professional standards, providing precise support for business expansion.CosyChem has been recognized as a national high-tech enterprise, a national “Specialized, Refined, Distinctive, and Innovative” (Specialized & New) Small Giant Enterprise, a national intellectual property advantage enterprise, as well as the Tianjin Enterprise Technology Center and Tianjin Intellectual Property Industry Operation Center. The company has accumulated over 180 invention patents and obtained CNAS and multiple international quality system certifications.
+ Intellectual Property
Item Technology Project
+ Partner
Committed to technological innovation and variety specialization
2011-2014
Certified as National High - Tech Enterprise
Certified as Tianjin Technology-Based Small and Medium-Sized Enterprise
Awarded the Tianjin Innovation Fund Support Project
Awarded the Tianjin Incubation Funding Support Project
Awarded the title of Tianjin Science and Technology Innovation Entrepreneur Talent
2015-2016
Completed the first pilot platform and put into operation
Obtained the Safety Production Standardization Certificate
Certified as National Recognized “Little Giants”Enterprise
2017-2018
Innovative drug intermediate production base put into operation
Completed the second pilot platform and put into operation
Certified as Tianjin Technology-Based Small and Medium-Sized Enterprise
Obtained the ISO 9001 Certification and ISO14001 Certification
2019-2020
CDMO business rapidly growing, with revenue of nearly 100 million
Obtained OHSAS18001 Certification
2021
Comprehensive upgrading of infrastructure and corporate culture
Confirmed the third five-year strategic plan
Completed financing of RMB one billion
Certified as Tianjin Gazelle Enterprise
Certified as Tianjin Leading Emerging Industry Enterprises
2022-2023
Recognized as a national “Specialized, Refined, Distinctive, and Innovative” (Specialized & New) Small Giant Enterprise
Obtained Tianjin Enterprise Technology Center
Obtained Tianjin Intellectual Property Industry Operation Center
Obtained CNAS
2024
Published LNPs achieving liver/muscle targeting results in Journal publication
Launched listing plan
Completed Pre-B of over 100 million yuan financing
Established of subsidiary - Cosychem Biotechnology
Obtained Tianjin Xingrui Enterprise and passed DCMM certification
2025-2026
Obtained as a national “Specialized, Refined, Distinctive, and Innovative” (Specialized & New) Small Giant Enterprise
Cooperation with Academician Chen Runsheng on non-coding RNA technology development
Construction of nucleic acid drug pilot platform and GMP base
Tianjin Postdoctoral Research Substation
IPO Preparation Stage
Published multiple high-impact papers in JMC, CEJ, etc., including breakthrough results on nucleic acid drugs for androgenetic alopecia
Leading in multiple national/industry/group standards for nucleic acid drug delivery, nucleotide sequence design, chemical modification, and gene therapy products
